• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

    11/8/24 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YMAB alert in real time by email
    • Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024
    • Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024
    • Achieved extension of primary DANYELZA U.S. patent through February 2034
    • Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from Turkey
    • Management reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment
    • The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET

    NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2024.

    "The third quarter of this year was one of continued focus and execution across our DANYELZA commercial business and our novel SADA PRIT radiopharmaceutical platform development pipeline," said Michael Rossi, President and Chief Executive Officer. "Physician usage of DANYELZA in the U.S. continues to remain very strong for patients with relapsed/refractory high-risk neuroblastoma. In addition, we continue to drive ex-U.S. market expansion with our new exclusive license and distribution agreement with Nobelpharma in Japan and the launch of our named patient program in Turkey. From a SADA PRIT pipeline standpoint, we expect to complete Part A of our GD2-SADA Phase 1 trial this year and present that data in the first quarter of next year."

    Third Quarter 2024 and Recent Corporate Highlights

    • Effective October 29, 2024, Y-mAbs entered into an exclusive license and distribution agreement with Nobelpharma for the development and commercialization of DANYELZA in Japan. Pursuant to the agreement, the Company recognized an upfront payment of $2.0 million in the fourth quarter of 2024. Y-mAbs is entitled to receive up to $31.0 million in product and commercial milestone payments in addition to profit sharing on the commercial sales of DANYELZA, if successfully approved and commercialized in Japan.
    • Y-mAbs received notification of the accepted patent extension for DANYELZA, US 9,315,585, through February 2034.
    • The Company's named patient program for DANYELZA launched in Turkey with partner TRPharm İlaç Sanayi Ticaret A.Ş. and TRPharm FZ-LLC.
    • Y-mAbs presented new clinical and preclinical data from studies evaluating anti-GD2 therapy naxitamab and the Company's first program from its Self-Assembly DisAssembly Radioimmunotherapy Technology Platform ("SADA PRIT"), GD2-SADA, respectively, in neuroblastoma in poster presentations at the American Academy of Cancer Research Special Conference in the Advanced in Pediatric Cancer Research on September 6-7, 2024 in Toronto, Canada.
    • The Company entered into a lease agreement for a term of ten years and nine months for office space in Princeton, New Jersey, where the Company plans to transition its headquarters in the first half of 2025 upon being provided access to the location.

    Financial Results

    Revenues

    Total net revenues for the quarter ended September 30, 2024 were $18.5 million, a 10% decline over total net revenues for the quarter ended September 30, 2023 of $20.5 million, which included $0.5 million in license revenue, primarily driven by decreased net product revenues in both U.S. and ex-U.S. markets.

    Total net revenues for the nine months ended September 30, 2024 were relatively flat compared to the nine months ended September 30, 2023, at $61.2 million and $61.5 million, respectively. The slight decrease was driven by a $0.7 million decrease in ex-U.S. DANYELZA net product revenues in the nine months ended September 30, 2024, which was partially offset by increased net product revenues in the U.S.

    The Company's U.S. DANYELZA net product revenues were $15.3 million and $16.1 million for the three months ended September 30, 2024 and 2023, respectively, representing a 5% decline, primarily due to an unfavorable price mix, partially offset by increased volume of 5% vial growth over the same time period.

    Y-mAbs' ex-U.S. DANYELZA net product revenues for the quarter ended September 30, 2024 were $3.1 million, a 19% decline from $3.9 million in the comparable period in 2023, primarily driven by decreased volume from Western Europe partially offset by volume increases in the remaining ex-U.S. territories.

    As of September 30, 2024, Y-mAbs had delivered DANYELZA to 68 centers across the U.S. since initial launch, with three new accounts added in the U.S. in the third quarter of 2024. During the quarter ended September 30, 2024, approximately 65% of the vials sold in the U.S. were sold outside of Memorial Sloan Kettering Cancer Center ("MSK"), compared to 67% in the second quarter ended June 30, 2024.

    The Company did not have license revenue for the quarter ended September 30, 2024. The Company had license revenues of $0.5 million for the nine months ended September 30, 2024, from its Latin America distribution partner, Adium, related to price approval for DANYELZA in Brazil from the Brazilian Medicines Market Regulation Chamber. The Company had license revenues of $0.5 million for the quarter and nine months ended September 30, 2023 from Adium, recognized upon the September 2023 achievement of marketing authorization for DANYELZA in Mexico.

    Operating Costs and Expenses

    Cost of Goods Sold

    Cost of goods sold were $2.3 million and $2.6 million for the quarter ended September 30, 2024 and 2023, respectively. Cost of goods sold were $7.4 million and $9.3 million for the nine months ended September 30, 2024 and 2023, respectively. Cost of goods sold included lower vial volumes of 1% and 37% in the three and nine months ended September 30, 2024, compared to the same periods in 2023, respectively. Cost of goods sold also included $0.4 million and $0.8 million inventory write-downs in the three and nine months ended September 30, 2023, respectively.

    The Company defines gross margin as net product revenues less cost of goods sold divided by net product revenues. The Company's gross margins was relatively unchanged in the quarter ended September 30, 2024, compared to the comparable periods in 2023. The Company's gross margins increased in the nine months ended September 30, 2024, compared to the comparable period in 2023, due to a favorable gross profit mix from revenue in international regions, particularly Eastern Asia that had an inventory stocking order in the nine months ended September 30, 2024, and inventory write-downs during the comparable periods in 2023, as noted above.

    Research and Development

    Research and development expenses were $11.2 million for the quarter ended September 30, 2024, a decrease of $4.2 million when compared with the same period in 2023. The decrease in research and development expenses was primarily attributable to the recognition of $4.1 million of milestone and license acquisition costs related to the Company's SADA license agreement during the three months ended September 30, 2023, as certain time-based clinical milestones within the agreement were determined to be probable based on the availability of necessary data and the assessment of clinical progress in the third quarter of 2023.

    For the nine months ended September 30, 2024, research and development expenses were $36.8 million, a decrease of $4.0 million when compared with the same period in 2023. The decrease in the research and development expenses was primarily attributable to recognition of $4.1 million of milestone and license acquisition costs related to the Company's SADA license agreement during the nine months ended September 30, 2023, as noted above.

    Selling, General, and Administrative

    Selling, general, and administrative expenses were $13.6 million and $10.2 million for the quarters ended September 30, 2024 and 2023, respectively. The $3.4 million increase in the selling, general and administrative expenses was primarily attributable to a $1.2 million increase related to the Company's former Chief Financial Officer's separation and consulting agreements, $1.1 million increase in personnel cost, inclusive of stock-based compensation and $0.5 million in professional and consulting fees.

    For the nine months ended September 30, 2024, selling, general, and administrative expenses were $42.3 million, an increase of $8.5 million compared with the same period in 2023. The increase was primarily attributable to a net impact of $3.6 million related to the settlement of a shareholder class-action lawsuit in the nine months ended September 30, 2024, and an additional legal settlement of $0.2 million in the nine months ended September 30, 2024. The increase also includes a $1.2 million increase related to our former Chief Financial Officer's separation and consulting agreements, a $1.1 million increase in personnel cost inclusive of stock-based compensation and $0.8 million in professional and consulting fees.

    Interest and Other Income

    Interest and other income were $1.9 million for the quarter ended September 30, 2024, as compared to $0.2 million for the quarter ended September 30, 2023. The increase of $1.7 million was primarily due to a $1.9 million of foreign currency transactional gains in the three months ended September 30, 2024, partially offset by a $0.2 million decrease in interest earned on the Company's cash and cash equivalents.

    For the nine months ended September 30, 2024 and 2023, the interest and other income was $3.0 and $2.4 million, respectively. The increase of $0.6 million was primarily due to $1.1 million of foreign currency transactional gains, partially offset by a $0.3 million decrease in interest earned on the Company's cash and cash equivalents.

    Net Loss

    Y-mAbs reported a net loss for the quarter ended September 30, 2024, of $7.0 million, or ($0.16) per basic and diluted share, compared to a net loss of $7.7 million, or ($0.18) per basic and diluted share, for the quarter ended September 30, 2023. The decrease in net loss for the quarter ended September 30, 2024 was primarily driven by decreased operating expenses and foreign currency transactional gains, partially offset by decreased net product revenue.

    For the nine months ended September 30, 2024, the Company reported a net loss of $22.9 million, or ($0.52) per basic and diluted share, as compared to net loss of $20.4 million, or ($0.47) per basic and diluted share, for the nine months ended September 30, 2023. The increase in net loss for the nine months ended September 30, 2024 was primarily driven by the net $3.8 million in charges related to the Company's two legal settlements, as described above.

    Cash and Cash Equivalents

    As of September 30, 2024, Y-mAbs had approximately $68.1 million in cash and cash equivalents. Cash utilized in the first three quarters of 2024 was $10.5 million, which was favorable relative to the Company's internal forecasts, and is on track to meet its corporate guidance for the full year 2024.

    2024 Financial Guidance

    Management reiterates its full year 2024 guidance:

    • Anticipated Total Net Revenues expected to be between $87 million and $95 million;
    • Anticipated Operating Expenses expected to remain between $115 million and $120 million;
    • Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and
    • Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.

    Webcast and Conference Call

    Y-mAbs will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET. To participate in the call, please use the following dial-in information:

    Investors (domestic): (877) 407-0792

    Investors (international): (201) 689-8263

    To access the live webcast, please use this link. Prior to the call and webcast, a slide presentation pertaining to the Company's quarterly earnings will be made available on the Investor Relations section of the Y-mAbs website, www.ymabs.com, shortly before the call begins.

    About Y-mAbs

    Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company's technologies include its investigational Self-Assembly DisAssembly ("SADA") Pretargeted Radioimmunotherapy Platform ("PRIT") and bispecific antibodies generated using the Y-BiClone platform. The Company's broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

    Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, use of cash and cash equivalents and DANYELZA product revenue and sufficiency of cash resources and related assumptions; expectations with respect to the Company's future financial performance; implied and express statements regarding the future of the Company's business, including with respect to expansion and its goals; expectations with respect to the Company's plans and strategies, development, regulatory, commercialization and product distribution plans, including the timing thereof; expectations with respect to the Company's products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA PRIT technology and potential benefits and applications thereof; expectations relating to key anticipated development milestones, including potential expansion and advancement of commercialization and development efforts, including potential indications, applications and geographies, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company's research and development programs, including with respect to timing and results; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; and other statements that are not historical facts. Words such as ‘‘anticipate,'' ‘‘believe,'' "contemplate," ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' "hope," ‘‘intend,'' ‘‘may,'' ‘‘might,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘should,'' ‘‘target,'' "will," ‘‘would',' "guidance," "goal," "objective," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company's financial condition and need for additional capital; the risks that actual results of the Company's restructuring plan and revised business plan will not be as expected; risks associated with the Company's development work; cost and success of the Company's product development activities and clinical trials; the risks of delay in the timing of the Company's or its partners' regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; risks related to the Company's dependence on third parties including for conduct of clinical testing and product manufacture as well as regulatory submissions; the Company's ability to enter into new partnerships or to recognize the anticipated benefits from its existing partnerships; risks related to government regulation; risks related to market approval, risks associated with protection of the Company's intellectual property rights; risks related to employee matters and managing growth; risks related to the Company's common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.

    Investor Contact:

    Courtney Dugan

    VP, Head of Investor Relations

    [email protected]



    Y-MABS THERAPEUTICS, INC.



    Consolidated Balance Sheets



    (unaudited)



    (In thousands, except share and per share data)
     
      September 30,  December 31, 
      2024

     2023

    ASSETS      
    CURRENT ASSETS      
    Cash and cash equivalents $68,122  $78,637 
    Accounts receivable, net  19,916   22,454 
    Inventories  9,557   5,065 
    Other current assets  1,462   4,955 
    Total current assets  99,057   111,111 
    Property and equipment, net  53   224 
    Operating lease right-of-use assets  1,075   1,412 
    Intangible assets, net  2,366   2,631 
    Other assets  18,366   12,491 
    TOTAL ASSETS $120,917  $127,869 
    LIABILITIES AND STOCKHOLDERS' EQUITY      
    LIABILITIES      
    Accounts payable $7,878  $6,060 
    Accrued liabilities  16,638   13,166 
    Operating lease liabilities, current portion  776   902 
    Total current liabilities  25,292   20,128 
    Accrued milestones  2,000   5,375 
    Operating lease liabilities, long-term portion  299   517 
    Other liabilities  897   864 
    TOTAL LIABILITIES  28,488   26,884 
    STOCKHOLDERS' EQUITY      
    Preferred stock, $0.0001 par value, 5,500,000 shares authorized and none issued at September 30, 2024 and December 31, 2023  —   — 
    Common stock, $0.0001 par value, 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 44,766,802 and 43,672,112 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively  4   4 
    Additional paid-in capital  572,807   558,002 
    Accumulated other comprehensive income  (36)  449 
    Accumulated deficit  (480,346)  (457,470)
    TOTAL STOCKHOLDERS' EQUITY  92,429   100,985 
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $120,917  $127,869 
     



    Y-MABS THERAPEUTICS, INC.



    Consolidated Statements of Net Loss and Comprehensive Loss



    (unaudited)



    (In thousands, except share and per share data)
                 
      Three months ended

    September 30, 
     Nine months ended

    September 30, 
      2024 2023 2024 2023
       
    REVENUES            
    Product revenue, net $18,461  $19,954  $60,690  $60,956 
    License revenue  —   500   500   500 
    Total revenues  18,461   20,454   61,190   61,456 
    OPERATING COSTS AND EXPENSES            
    Cost of goods sold  2,248   2,595   7,359   9,327 
    License royalties  —   50   50   50 
    Research and development  11,168   15,358   36,776   40,831 
    Selling, general, and administrative  13,613   10,200   42,270   33,721 
    Total operating costs and expenses  27,029   28,203   86,455   83,929 
    Loss from operations  (8,568)  (7,749)  (25,265)  (22,473)
    OTHER INCOME, NET            
    Interest and other income  1,916   189   2,995   2,400 
    LOSS BEFORE INCOME TAXES  (6,652)  (7,560)  (22,270)  (20,073)
    Provision for income taxes  346   187   606   366 
    NET LOSS $(6,998) $(7,747) $(22,876) $(20,439)
    Other comprehensive income/(loss)            
    Foreign currency translation  (1,083)  806   (485)  518 
    COMPREHENSIVE LOSS $(8,081) $(6,941) $(23,361) $(19,921)
    Net loss per share attributable to common stockholders, basic and diluted $(0.16) $(0.18) $(0.52) $(0.47)
    Weighted average common shares outstanding, basic and diluted  44,626,943   43,620,532   44,145,183   43,651,536 
     



    Y-MABS THERAPEUTICS, INC.



    Consolidated Statements of Cash Flows



    (unaudited)



    (In thousands)
           
      Nine months ended

    September 30, 
      2024 2023
    CASH FLOWS FROM OPERATING ACTIVITIES      
    Net loss $(22,876) $(20,439)
    Adjustments to reconcile net loss to net cash used in operating activities:      
    Depreciation and amortization  433   574 
    Stock-based compensation  11,480   11,330 
    Foreign currency and other transactions  (456)  (369)
    Changes in assets and liabilities:      
    Accounts receivable, net  2,538   (6,343)
    Inventories  (4,492)  (411)
    Other current assets  3,493   2,671 
    Other assets  (5,875)  (3,735)
    Accounts payable  2,274   (6,196)
    Accrued liabilities and other  (363)  3,722 
    NET CASH USED IN OPERATING ACTIVITIES  (13,844)  (19,196)
    CASH FLOWS FROM INVESTING ACTIVITIES  —   — 
    CASH FLOWS FROM FINANCING ACTIVITIES      
    Proceeds from exercised stock options  3,325   — 
    NET CASH PROVIDED BY FINANCING ACTIVITIES  3,325   — 
    Effect of exchange rates on cash and cash equivalents  4   5 
    NET DECREASE IN CASH AND CASH EQUIVALENTS  (10,515)  (19,191)
    Cash and cash equivalents at the beginning of period  78,637   105,762 
    Cash and cash equivalents at the end of period $68,122  $86,571 
           
    SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES      
    Right-of-use assets obtained in exchange for lease obligations $320  $636 
    Acquisition of treasury shares upon repayment of secured promissory note $—  $480 
     


    Primary Logo

    Get the next $YMAB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $YMAB

    DatePrice TargetRatingAnalyst
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    11/18/2024$23.00Outperform
    Oppenheimer
    8/16/2024$20.00Overweight
    Cantor Fitzgerald
    6/28/2024$21.00Buy
    Truist
    5/10/2023$5.00 → $13.00Neutral → Outperform
    Wedbush
    4/3/2023Buy → Neutral
    Guggenheim
    1/27/2023$4.00Equal-Weight → Underweight
    Morgan Stanley
    1/5/2023Outperform → Market Perform
    Cowen
    More analyst ratings

    $YMAB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

      Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

      3/21/24 10:20:07 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Y-mAbs Therapeutics Inc.

      DEFA14A - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/30/25 4:13:09 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Y-mAbs Therapeutics Inc.

      DEF 14A - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/30/25 4:10:32 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/28/25 7:04:45 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

      Company's Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTAIncreased tumor retention and total tumor uptake anticipated by using optimized universal RadiohaptenCompany plans to initiate a Trial 1001 Bridge study (Part 2A) with optimized Radiohapten, "Proteus", in 1H 2026 with data readout in 2H 2026; Part B of Trial 1001 anticipated to initiate with Proteus in 1H 2027 with data readout in 2H 2027Expanded Radiopharmaceutical pipeline to focus on target franchise areas in oncology, with specific prog

      5/28/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

      PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma Research Meeting ("ANR") being held on May 25-28, 2025 in Washington, D.C. The trial in progress poster titled "A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients wit

      5/26/25 10:00:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

      PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will hold a virtual Radiopharmaceutical R&D update at 8:00 a.m. ET on Wednesday, May 28, 2025. During the virtual Radiopharmaceutical R&D update, Y-mAbs will discuss: Part A clinical data from the Company's ongoing Phase 1 GD2-SADA clinical trial (Trial 1001), including pharmacokinetic and dosimetry data; updates around the Company's nonclinical optimization studies

      5/13/25 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tyagi Ashu was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      7/2/25 4:20:24 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hamill Laura was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      7/2/25 4:20:27 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wedell-Wedellsborg Johan was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      7/2/25 4:20:21 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Y-mAbs Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Y-mAbs Therapeutics from Neutral to Underperform and set a new price target of $3.00

      4/22/25 7:23:34 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target

      Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00

      11/18/24 8:23:54 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00

      8/16/24 7:40:36 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/12/23 8:27:16 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/12/23 8:26:25 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wg Biotech Aps bought $40,190 worth of shares (6,183 units at $6.50) and bought $850,222 worth of shares (121,366 units at $7.01), increasing direct ownership by 3% to 4,552,778 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/11/23 5:25:50 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

      NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co

      1/10/25 7:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

      NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre

      7/1/24 4:05:00 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

      NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop

      6/5/24 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Financials

    Live finance-specific insights

    See more
    • Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

      Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv

      5/13/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

      PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, May 13, 2025 at 8:00 a.m. ET. A live audio webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.ymabs.com/events-and-presentat

      5/6/25 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

      Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR

      3/4/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/14/24 4:32:10 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/12/24 6:00:40 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/4/24 2:16:23 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care